Gilead SciencesGILD
NASDAQ · USA · Segment 3 of 8 in the Medicine, pharma & life science value chain: Biotech & innovation
American biotech company and global leader in HIV treatment, with a growing oncology portfolio.
Biotech & innovation: Innovation-driven biotech companies focused on novel treatment modalities.
Key metrics
Market cap
$166B
Price
$130.11
Today
−3.5%
Return YTD
+9.9%
Return 1Y
+19.1%
P/E
18.0
P/S
5.6
P/B
7.1
Data as of 2026-07-10 · updates daily after U.S. close
Theme exposure
In the value chain
Products & services
- HIV (Biktarvy)
- Oncology (cell therapy)
- Liver diseases
Competitors
- GSK/ViiV
- Merck
- Bristol Myers Squibb
Risks
- Dependence on HIV franchise
- Pipeline execution
Same segment: Biotech & innovation
See where Gilead Sciences sits in the full Medicine, pharma & life science map — every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →